Panmure Gordon reissued their buy rating on shares of Scancell Holdings Plc (LON:SCLP) in a report released on Monday morning. The brokerage currently has a GBX 68 ($0.84) price objective on the stock.

Shares of Scancell Holdings Plc (LON:SCLP) opened at 16.50501 on Monday. Scancell Holdings Plc has a 12-month low of GBX 12.00 and a 12-month high of GBX 25.90. The firm’s 50-day moving average is GBX 16.88 and its 200 day moving average is GBX 17.16. The stock’s market capitalization is GBX 43.17 million.

About Scancell Holdings Plc

Scancell Holdings plc develops immunotherapies for the treatment of cancer. The Company develops immunotherapies based on its ImmunoBody and Moditope technology platforms. Its ImmunoBody, SCIB1, is being developed for treatment of melanoma and is being evaluated in Phase I/II clinical trial. Its clinical trials demonstrated that SCIB1, when used as monotherapy, has an effect on tumor load, produces a melanoma-specific immune response and survival trend without serious side effects.

Receive News & Stock Ratings for Scancell Holdings Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell Holdings Plc and related stocks with our FREE daily email newsletter.